{"protocolSection":{"identificationModule":{"nctId":"NCT01141153","orgStudyIdInfo":{"id":"MUSICA-2"},"secondaryIdInfos":[{"id":"2009-017256-27","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Hospital Universitari Vall d'Hebron Research Institute","class":"OTHER"},"briefTitle":"Anticoagulation in Stent Intervention","officialTitle":"Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation","acronym":"MUSICA-2"},"statusModule":{"statusVerifiedDate":"2015-02","overallStatus":"UNKNOWN","lastKnownStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-06"},"primaryCompletionDateStruct":{"date":"2015-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2015-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2010-06-09","studyFirstSubmitQcDate":"2010-06-09","studyFirstPostDateStruct":{"date":"2010-06-10","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-02-23","lastUpdatePostDateStruct":{"date":"2015-02-24","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hospital Universitari Vall d'Hebron Research Institute","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Objective:\n\nThe main objective is to evaluate the pattern of dual antiplatelet therapy (aspirin, 300 mg / day + clopidogrel 75 mg / day) compared to the use of the triple regimen (Acenocoumarol as control + acetylsalicylic acid 100 mg / day + Clopidogrel 75 mg / day) in patients with atrial fibrillation, low-moderate risk of stroke (CHADS ≤ 2) who are undergoing PCI-S.\n\nDesign:\n\nRandomized, parallel, with two arms, blind evaluation by third parties.\n\nPatients:\n\n304 patients undergoing PCI-S with atrial fibrillation, low-moderate risk of stroke (CHADS ≤ 2), which requires prevention of thrombosis"},"conditionsModule":{"conditions":["Atrial Fibrillation","Stroke"],"keywords":["atrial fibrillation","Coronary Stent implantation","Low-moderate risk of stroke","dual antiplatelet therapy","anticoagulation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":304,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Oral anticoagulation plus dual antiplatelet therapy","type":"EXPERIMENTAL","interventionNames":["Drug: Acetylsalicylic Acid + clopidogrel + acenocoumarol"]},{"label":"Dual antiplatelet therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Acetylsalicylic Acid + clopidogrel"]}],"interventions":[{"type":"DRUG","name":"Acetylsalicylic Acid + clopidogrel + acenocoumarol","description":"Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring\n\nTreatment : 6 weeks for bare metal stent and 12 months for drug elution stent","armGroupLabels":["Oral anticoagulation plus dual antiplatelet therapy"]},{"type":"DRUG","name":"Acetylsalicylic Acid + clopidogrel","description":"Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily\n\nTreatment : 6 weeks for bare metal stent and 12 months for drug elution stent.","armGroupLabels":["Dual antiplatelet therapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"A composite of stroke, myocardial infarction, systemic thromboembolism, stent thrombosis and death","description":"Incidence of the composite major events (stroke, myocardial infarction, systemic thromboembolism, stent thrombosis and death) until 12 months after the initial treatment","timeFrame":"until 12 months"}],"secondaryOutcomes":[{"measure":"Incidence of major and minor bleeding","timeFrame":"until 12 months"},{"measure":"Adverse events","timeFrame":"until 12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients of both sexes older than 18 years.\n* Patients with permanent atrial fibrillation, persistent or paroxysmal (at least one episode), documented electrocardiographically and receiving oral anticoagulation. Patients with acute coronary syndrome or stable angina who are undergoing PCI-S.\n* Patients who have previously given their informed consent to participation in the study.\n\nExclusion Criteria:\n\n* Patients who can not be followed by the research team during the 12 months provided for monitoring.\n* Patients with renal failure or serum creatinine above 2 mg • dL-1, neurological deficits, active ulcer or epigastric pain.\n* Patients who continue regular treatment with NSAIDs or other analgesics or corticosteroids.\n* Patients undergoing reoperation.\n* Patients who during the study period, should receive, according to medical criteria, other adjuvant drug treatment than that specified in this protocol.\n* Pregnant women.\n* Use of investigational agents or not registered within 30 days of entry into the study.\n* Patients with a history of allergy to study drugs or excipients.\n* Patients with severe valve disease.\n* Patients with CHADS\\> 2.\n* Patients who can not use the study drug orally.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Antonia Sambola, MD Ph","role":"PRINCIPAL_INVESTIGATOR"},{"name":"David García -Dorado, MD Ph","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Hospital Germans Trias i Pujol","city":"Badalona","state":"Barcelona","zip":"08916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Hospital Universitari de Bellvitge","city":"Hospitalet de Llobregat","state":"Barcelona","zip":"08907","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Corporación Sanitaria Parc Taulí","city":"Sabadell","state":"Barcelona","zip":"08208","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}},{"facility":"Hospital Marqués de Valdecilla","city":"Santander","state":"Cantabria","zip":"39011","country":"Spain","geoPoint":{"lat":43.46472,"lon":-3.80444}},{"facility":"Hospital Puerta del Hierro","city":"Majadahonda","state":"Madrid","zip":"28222","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}},{"facility":"Hospital Sant Pau","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Vall d'Hebron","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Clínic de Barcelona","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Dr.Josep Trueta","city":"Girona","zip":"17007","country":"Spain","geoPoint":{"lat":41.98311,"lon":2.82493}},{"facility":"Hospital Universitario Gregorio Marañón","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital San Carlos","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}}]},"referencesModule":{"references":[{"pmid":"24093846","type":"DERIVED","citation":"Sambola A, Montoro JB, Del Blanco BG, Llavero N, Barrabes JA, Alfonso F, Bueno H, Cequier A, Serra A, Zueco J, Sabate M, Rodriguez-Leor O, Garcia-Dorado D. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial. Am Heart J. 2013 Oct;166(4):669-75. doi: 10.1016/j.ahj.2013.07.028. Epub 2013 Sep 14."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"D000000074","term":"Acenocoumarol"},{"id":"D000077144","term":"Clopidogrel"}],"ancestors":[{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000058921","term":"Purinergic P2Y Receptor Antagonists"},{"id":"D000058919","term":"Purinergic P2 Receptor Antagonists"},{"id":"D000058914","term":"Purinergic Antagonists"},{"id":"D000058905","term":"Purinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M21679","name":"Salicylic Acid","relevance":"LOW"},{"id":"M4238","name":"Aspirin","asFound":"Barriers","relevance":"HIGH"},{"id":"M1669","name":"Clopidogrel","asFound":"Results","relevance":"HIGH"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M1271","name":"Acenocoumarol","asFound":"Belinostat","relevance":"HIGH"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M28984","name":"Purinergic P2Y Receptor Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"Derm","name":"Dermatologic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"AnCoag","name":"Anticoagulants"}]}},"hasResults":false}